MedTrace Logo

Geriatric Assessment and Technology Evaluation in Prostate Cancer

NCT06215508 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-06-08

No results posted yet for this study

Summary

By doing this study, doctors hope to learn more about factors that contribute to frailty (a condition where older adults feel weak, get tired easily, and struggle more with everyday activities) and serious side effects among men over the age of 65 who will receive androgen deprivation therapy (also called "hormone therapy") for prostate cancer that has spread to other parts of their body. Participation in this research will last about 5 years. For the first year, participants will have 5 study visits where they have give blood samples, answer survey questions, and use a wearable device. After study visits are complete, there is a 4-year follow-up period. Research team will check regular doctor visits and look at participants' medical records.

Conditions

Interventions

OTHER

Questionnaires

Questionnaires participants fill out at different study visits

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Eligibility

Min Age
18 Minutes
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2031-04-30
Completion
2031-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06215508 on ClinicalTrials.gov